Personalis (NASDAQ:PSNL) Rating Lowered to Sell at Wall Street Zen

Personalis (NASDAQ:PSNL) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other equities research analysts have also recently commented on PSNL. Needham & Company LLC lifted their target price on Personalis from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Lake Street Capital reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Personalis in a research report on Wednesday, November 5th. Morgan Stanley increased their target price on shares of Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a research report on Monday, December 1st. Guggenheim raised their price target on shares of Personalis from $6.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, November 11th. Finally, BTIG Research lifted their price target on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $10.57.

Personalis Stock Performance

NASDAQ:PSNL opened at $9.56 on Friday. Personalis has a 52 week low of $2.83 and a 52 week high of $11.40. The firm has a 50-day moving average price of $8.77 and a two-hundred day moving average price of $6.76. The firm has a market cap of $848.93 million, a price-to-earnings ratio of -10.86 and a beta of 1.99.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.04. The firm had revenue of $14.50 million for the quarter, compared to the consensus estimate of $13.31 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%. As a group, sell-side analysts forecast that Personalis will post -1.4 earnings per share for the current year.

Insider Buying and Selling at Personalis

In related news, CFO Aaron Tachibana sold 103,668 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $10.78, for a total transaction of $1,117,541.04. Following the sale, the chief financial officer directly owned 164,458 shares in the company, valued at approximately $1,772,857.24. The trade was a 38.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Christopher M. Hall sold 29,612 shares of the stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total value of $266,211.88. Following the sale, the chief executive officer directly owned 148,486 shares in the company, valued at $1,334,889.14. This trade represents a 16.63% decrease in their position. The disclosure for this sale is available in the SEC filing. 3.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Personalis

Several hedge funds have recently bought and sold shares of PSNL. Oracle Investment Management Inc. purchased a new stake in Personalis in the 3rd quarter worth approximately $1,496,000. XTX Topco Ltd bought a new position in shares of Personalis in the third quarter worth $539,000. Millennium Management LLC raised its holdings in shares of Personalis by 11.0% in the 3rd quarter. Millennium Management LLC now owns 1,210,754 shares of the company’s stock valued at $7,894,000 after acquiring an additional 120,027 shares in the last quarter. Brevan Howard Capital Management LP bought a new stake in Personalis during the third quarter valued at approximately $97,000. Finally, Brooklyn Investment Group bought a new stake in shares of Personalis during the 3rd quarter worth $723,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.